Page last updated: 2024-09-03

gefitinib and Experimental Hepatoma

gefitinib has been researched along with Experimental Hepatoma in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Kengen, J1
Böhning, E; Calvisi, DF; Cigliano, A; Dombrowski, F; Evert, M; Günther, J; Merz, J; Peters, K; Pilo, MG; Ribback, S; Sailer, V; Steinmüller, F; Utpatel, K1
Aoudjehane, L; Barbu, V; Blivet-Van Eggelpoël, MJ; Chettouh, H; Desbois-Mouthon, C; Fartoux, L; Housset, C; Priam, S; Rey, C; Rosmorduc, O1
Basaki, Y; Kuwano, M; Ogawa, K; Ono, M; Sakisaka, S; Ueda, S; Yoshie, M1

Other Studies

4 other study(ies) available for gefitinib and Experimental Hepatoma

ArticleYear
Tumor reoxygenation following administration of the EGFR inhibitor, gefitinib, in experimental tumors.
    Advances in experimental medicine and biology, 2013, Volume: 789

    Topics: Animals; Cell Hypoxia; Electron Spin Resonance Spectroscopy; ErbB Receptors; Fibrosarcoma; Gefitinib; Liver Neoplasms, Experimental; Mice; Mice, Inbred C3H; Oximetry; Oxygen; Oxygen Consumption; Quinazolines

2013
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.
    International journal of molecular sciences, 2016, Sep-23, Volume: 17, Issue:10

    Topics: Animals; Cell Proliferation; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Islets of Langerhans Transplantation; Liver Neoplasms, Experimental; Male; Nitrosamines; Protein Kinase Inhibitors; Quinazolines; ras Proteins; Rats; Rats, Inbred Lew; Sodium-Glucose Transporter 1; Thyroid Epithelial Cells; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha

2016
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
    Journal of hepatology, 2012, Volume: 57, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Division; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Hep G2 Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-3; Sorafenib; Xenograft Model Antitumor Assays

2012
PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib.
    Cancer research, 2006, May-15, Volume: 66, Issue:10

    Topics: Animals; Antineoplastic Agents; Cell Growth Processes; Chemokine CXCL1; Chemokines, CXC; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Dosage; Genes, erbB-1; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A

2006
chemdatabank.com